Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The medicines are the first to slow the disease, which may give people extra time living independently.

The decision to block Alzheimer’s ‘wonder’ drugs for use by NHS patients will be appealed against. The two breakthrough drugs, proven to slow the onset of Alzheimer’s disease, have been rejected for use on the NHS by the National Institute for Health and Care Excellence (Nice).